Volume 5, Issue 1

Two Drugs — The New ART Paradigm?

In this issue:

The current gold standard for HIV treatment — triple drug therapy — is evolving. Dual drug regimens — two drugs from two separate classes — are becoming the new consensus. But which agents are most appropriate for patients starting initial treatment? Which should be used for those currently virologically suppressed and wanting to switch for regimen simplification? What does the evidence say, and what do the experts recommend?

In this issue, Dr. Ethel Weld, Assistant Professor of Medicine, Pharmacology and Molecular Sciences at the Johns Hopkins School of Medicine, analyzes the current research and provides answers to help guide these important decisions.

Learning objectives:

  • Explain the appropriate use of dolutegravir-containing two-drug regimens in ART-naïve individuals with HIV or as switch regimens in individuals who are already virologically suppressed. 
  • Describe the clinical situations where dual therapy should NOT be used.

Author:

Ethel D. Weld, MD, PhD
Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland

Program Directors:

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California

Justin Alves, RN, ACRN, CARN

Nurse Educator – Office Based Addiction Treatment, Training and Technical Assistance Program
Boston Medical Center
Boston, Massachusetts

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: December 16, 2019
Expiration date: December 15, 2021